Why Invest in Next-Generation Sequencing (NGS)?
The COVID-19 pandemic has shone new light on the importance of genomic sequencing in understanding pathogens and controlling the spread of disease. Harnessing the transformative power of this technology, including in response to SARS-CoV-2, requires the active engagement from a broad spectrum of stakeholders, from ASM members working in research laboratories, academic medical centers, hospitals and clinical microbiology laboratories, industry partners and public health labs. Supporting and advancing pathogen genomics surveillance and sequencing across the field is a top priority for ASM.
What ASM Is Doing
In the News
- ASM and Partners Request $60M for AMD Program at CDC
- ASM Hails Game-Changing Investment in Genomic Surveillance Enacted in American Rescue Plan
- ASM and Stakeholders Endorse Tracking COVID-19 Variants Act
- The Hot Zone Meets the Genome: Staying Ahead of the Next Outbreak Through Advanced Molecular Detection
Hear From Experts
The entire TWiV team assembles to discuss resurgence of COVID-19 in Manaus, Brazil, discovery of SARS-CoV-2 related viruses in bats in Southeast Asia and increased Ct values after administration of mRNA vaccine.
- Search for articles about AMD in ASM Journals.
- ASM's COVID-19 Research Registry was designed for the scientific research community to serve as a trusted source for credible science about COVID-19 and coronaviruses, in general. Over 30,000 visitors have accessed the registry which includes a growing number of carefully-reviewed published and pre-print articles.
- Next Generation Sequencing for Infectious Disease Diagnostics: Dr. Catherine Hogan and Dr. Alex Greninger present the session “Next Generation Sequencing for Infectious Diseases Diagnostics” at ASM’s World Microbe Forum 2021.